AstraZeneca's £2.8bn shot following upgrade
Portfolio Pulse from
AstraZeneca's shares rose by 1.6% after UBS upgraded its rating to 'buy' and increased the price target, citing a strong drug pipeline and long-term growth potential.
February 13, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's shares increased by 1.6% after UBS upgraded its rating to 'buy' and raised the price target from £115 to £142, due to a strong drug pipeline and growth potential.
The upgrade by UBS and the increase in price target are positive signals for AstraZeneca, indicating confidence in its future performance. This is likely to attract more investors, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100